Provided by Tiger Fintech (Singapore) Pte. Ltd.

Trevi Therapeutics, Inc.

6.07
-0.0500-0.82%
Post-market: 6.140.0700+1.15%19:09 EDT
Volume:1.43M
Turnover:8.72M
Market Cap:723.21M
PE:-13.65
High:6.24
Open:6.12
Low:5.98
Close:6.12
Loading ...

Q4 2024 Trevi Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents
·
19 Mar

Trevi Therapeutics Inc : Needham Cuts Target Price to $24 From $25

THOMSON REUTERS
·
19 Mar

Stifel Nicolaus Reaffirms Their Buy Rating on Trevi Therapeutics (TRVI)

TIPRANKS
·
19 Mar

Trevi Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
19 Mar

Trevi Therapeutics 4Q Loss Widens, Cough Treatment Trials Move Forward

Dow Jones
·
19 Mar

Trevi Therapeutics: Completed Enrollment in Phase 2B Coral Trial in Ipf Patients With Chronic Cough in Feb 2025, With Topline Data Expected in Q2 2025

THOMSON REUTERS
·
19 Mar

Trevi Therapeutics: Ended 2024 With $107.6 Mln in Cash, Cash Equivalents & Marketable Securities, With Expected Cash Runway Into Second Half of 2026

THOMSON REUTERS
·
19 Mar

Trevi Therapeutics Q4 Pretax Profit USD -11.399 Million

THOMSON REUTERS
·
19 Mar

Press Release: Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates

Dow Jones
·
19 Mar

Trevi Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview

Reuters
·
15 Mar

Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025

PR Newswire
·
12 Mar

TRVI Stock Soars on Meeting Primary Goal in Chronic Cough Study

Zacks
·
11 Mar

Analysts Have Conflicting Sentiments on These Healthcare Companies: BioNTech SE (BNTX) and Trevi Therapeutics (TRVI)

TIPRANKS
·
11 Mar

HC Wainwright Adjusts Trevi Therapeutics Price Target to $12.50 From $7.50, Maintains Buy Rating

MT Newswires Live
·
11 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Willis Lease Finance, CME Group

Reuters
·
11 Mar

Leerink Adjusts Price Target on Trevi Therapeutics to $11 From $7, Maintains Outperform Rating

MT Newswires Live
·
10 Mar

Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps

Benzinga
·
10 Mar

Trevi Therapeutics Inc : Leerink Partners Raises Target Price to $11 From $7

THOMSON REUTERS
·
10 Mar

Trevi Shares Climb On Positive Results for Chronic Cough Treatment

Dow Jones
·
10 Mar

Trevi Therapeutics Shares Jump Over 60% After Cough Therapy Succeeds in Mid-Stage Trial

THOMSON REUTERS
·
10 Mar